209 related articles for article (PubMed ID: 21606168)
1. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.
Nakagawa M; Tsuzuki S; Honma K; Taguchi O; Seto M
Haematologica; 2011 Sep; 96(9):1318-26. PubMed ID: 21606168
[TBL] [Abstract][Full Text] [Related]
2. [Aggressive B-cell lymphoma with IGH/MYC, IGH/BCL2, and IGH/CCND1 translocations].
Nishijima A; Noguchi Y; Narukawa K; Takano H; Oshikawa G
Rinsho Ketsueki; 2019; 60(10):1425-1430. PubMed ID: 31695002
[TBL] [Abstract][Full Text] [Related]
3. Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene.
Kanda-Akano Y; Nomura K; Fujita Y; Horiike S; Nishida K; Nagai M; Miura I; Nakamura S; Seto M; Iida S; Ueda R; Taniwaki M
Leuk Lymphoma; 2004 Aug; 45(8):1559-67. PubMed ID: 15370207
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
5. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
6. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
Leskov I; Pallasch CP; Drake A; Iliopoulou BP; Souza A; Shen CH; Schweighofer CD; Abruzzo L; Frenzel LP; Wendtner CM; Hemann MT; Chen J
Oncogene; 2013 Feb; 32(8):1066-1072. PubMed ID: 22484426
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
8. Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Junk DJ; Cipriano R; Stampfer M; Jackson MW
PLoS One; 2013; 8(2):e53776. PubMed ID: 23390492
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
10. Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
da Cunha Santos G; Ko HM; Saieg MA; Boerner SL; Lai SW; Bailey D; Geddie WR
Cancer Cytopathol; 2011 Aug; 119(4):254-62. PubMed ID: 21560251
[TBL] [Abstract][Full Text] [Related]
11. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
12. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
13. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
[TBL] [Abstract][Full Text] [Related]
14. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
15. Current perspectives in genetics of "double-hit" lymphoma with possible clinical implications.
Song YY; Tan YH; Yuan Y; Guo W; Pan ZY; Bai O
Cell Biochem Biophys; 2014 Jun; 69(2):203-8. PubMed ID: 24234731
[TBL] [Abstract][Full Text] [Related]
16. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
17. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.
Lovec H; Grzeschiczek A; Kowalski MB; Möröy T
EMBO J; 1994 Aug; 13(15):3487-95. PubMed ID: 8062825
[TBL] [Abstract][Full Text] [Related]
19. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Drexler HG; Eberth S; Nagel S; MacLeod RA
Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
